Table 6 |
||
|
Effect of PPAR-γ agonists on biochemical markers of bone turnover in rats with adjuvant arthritis |
||
|
Group |
Change in plasma osteocalcina (ng/ml) |
Change in urinary deoxypyridinolineb (nmol/mmol creatinine) |
|
|
||
|
Normal controls |
-39 ± 11 |
-3 ± 6 |
|
AIA controls |
-50 ± 9 |
24 ± 7* |
|
AIA + ROSI 10 |
-37 ± 12 |
9 ± 4 |
|
AIA + PIO 30 |
-32 ± 16 |
12 ± 5 |
|
|
||
|
PPAR, peroxisome proliferator-activated receptor; AIA, adjuvant-induced arthritis; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 mg/kg/day. Data are expressed as means ± SEM (n = 5 for deoxypyridinoline; n = 6 for osteocalcin). *, P < 0.05 compared with normal controls (ANOVA and Fisher's PLSD test). aDay 21 minus day -1; bday 21 minus day 0. |
||
|
Koufany et al. Arthritis Research & Therapy 2008 10:R6 doi:10.1186/ar2354 |
||
